A Fluicell ready to address future health challenges
Over the past year, Fluicell has made significant progress in the development of bioprinted tissue-based products for therapeutic purposes and for drug screening, partly through our various collaborations and partnerships, but also through our own internal development work. These advances now form the foundation for a new strategic direction for Fluicell, based on accelerating the development of tissue-based products, with a particular focus on synthetic pancreatic islets for the treatment of type 1 diabetes.
On November 2, 10:00, Fluicell’s CEO Carolina Trkulja will give a presentation focusing on Fluicell’s new long-term strategy and our position on the markets for advanced therapies and tissue-based screening products.
You can view the presentation live here: https://www.finwire.tv/webcast/fluicell/investerarpresentation/.
The presentation will be given in Swedish, but a recorded version with English subtitles will be made available on our website.